CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 6939-A |

# Specialty Guideline Management Vanrafia

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Vanrafia | atrasentan |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indication1

Vanrafia is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 grams per gram (g/g).

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

* Initial requests:
  + Kidney biopsy confirming a diagnosis of primary immunoglobulin A nephropathy (IgAN).
  + Laboratory report and/or chart note(s) indicating the member has proteinuria greater than or equal to 1 gram per day (g/day) or baseline urine protein-to-creatinine ratio (UPCR) greater than or equal to 0.8 grams per gram (g/g).
* Continuation requests:
  + Laboratory report and/or chart note(s) indicating the member has decreased levels of proteinuria or UPCR from baseline.

## Coverage Criteria

### Primary Immunoglobulin A Nephropathy (IgAN)1-3

Authorization of 12 months may be granted when all of the following criteria are met:

* Member has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy.
* Member has either of the following:
  + - Proteinuria greater than or equal to 1 g/day;
    - UPCR greater than or equal to 0.8 g/g
* Member is receiving a stable dose of maximally tolerated renin-angiotensin system (RAS) inhibitor therapy (e.g., angiotensin converting enzyme inhibitor [ACEI] or angiotensin II receptor blocker [ARB]) for at least 3 months of therapy, or member has an intolerance or contraindication to RAS inhibitors.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in all members (including new members) who are currently receiving the requested medication and who are experiencing benefit from therapy as evidenced by either of the following:

* Decreased levels of proteinuria from baseline.
* Decrease in UPCR from baseline.

## References

1. Vanrafia [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation; April 2025.
2. ClinicalTrial.gov. National Library of Medicine (US). Identifier NCT04573478 Atrasentan in Patients with IgA Nephropathy (ALIGN). October 15, 2024. Available from: https://clinicaltrials.gov/study/NCT04573478.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases*. Kidney Int.* 2021 Oct; 100 (4S): S1-S276. doi: 10.1016/j.kint.2021.05.021.